You are here

Developing Novel Therapies for Treating Breast-Cancer-Related Lymphedema

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41CA183335-01
Agency Tracking Number: R41CA183335
Amount: $225,000.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NCI
Solicitation Number: PA13-089
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
3353 ALMA ST, STE 245
PALO ALTO, CA 94306-3514
United States
DUNS: 78502248
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (650) 723-7057
Business Contact
Phone: (650) 799-3496
Research Institution
STANFORD, CA 94304-1222
United States

 () -
 Nonprofit College or University

DESCRIPTION (provided by applicant): Destruction of lymphatic vessels during the treatment of breast cancer by surgery and/or radiation therapy can lead to the development of secondary lymphedema. The breast-cancer-related lymphedema is associated with debilitating limb swelling, chronic inflammation, tissue fibrosis, and increased susceptibility to infection. It has been estimated that approximately 20% of the 2.3 million breast cancer survivors in the US suffer this chronic condition following axillary lymph node dissection and radiation therapy. Current treatments for secondary lymphedema are limited to lifelong physiotherapies, which can cause substantial and even prohibitive financial, physical, and psychological strain for most patients. Clearly, thereis an unmet yet urgent medical need for new approaches to treat lymphedema in breast cancer survivors. Interestingly, recent discoveries have shown that two human hormones-adrenomedullin (ADM) and intermedin (IMD/ADM2)-and their cognate receptors (CL

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government